Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
Please note the ANZCTR will be unattended on Monday the 7th of October for the Labour Day public holiday.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12621000459820
Ethics application status
Approved
Date submitted
30/11/2020
Date registered
20/04/2021
Date last updated
31/05/2022
Date data sharing statement initially provided
20/04/2021
Type of registration
Prospectively registered
Titles & IDs
Public title
Relative Evaluation of the benefit of Cilnidipine ON the Nature, Observational Indices, Temperature changes, and overall Effect in secondary Raynaud’s disease (RECONNOITER-1)
Query!
Scientific title
A Randomized, Placebo-controlled Phase 2a Study to Assess the Safety and Efficacy of Cilnidipine (10 mg and 20 mg) Alone and in Combination with 5 mg Tadalafil, in Participants with Diagnosis of Secondary Raynaud’s Disease,
Query!
Secondary ID [1]
302621
0
None
Query!
Universal Trial Number (UTN)
U1111-1260-1080
Query!
Trial acronym
RECONNOITER-1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Raynaud's syndrome
319512
0
Query!
Condition category
Condition code
Cardiovascular
317469
317469
0
0
Query!
Other cardiovascular diseases
Query!
Inflammatory and Immune System
318680
318680
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Each participant will self-administer 1 tablet and 1 capsule daily for 12 consecutive days. Depending on which arm the participants get randomised, they will receive either 10 mg or 20 mg Cilnidipine tablet or placebo tablet and 5 mg of Tadalafil capsule or placebo capsule.
Query!
Intervention code [1]
318901
0
Treatment: Drugs
Query!
Comparator / control treatment
The placebo glucose tablet matches the study drug in weight and appearance and do not contain the active ingredient of the study drug.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
325499
0
Percentage change from baseline in frequency of Raynaud's Phenomenon (RP) attacks. Participants record RP attacks in the e-diary and this will be assessed daily by the researcher.
Query!
Assessment method [1]
325499
0
Query!
Timepoint [1]
325499
0
Primary Outcome will be percentage change from baseline in frequency of weekly RP attacks.
This are self-recorded by the participants in the e-diary. This will be reviewed daily by the researchers, and analysed weekly for percentage change in the frequency of the attack.
Query!
Secondary outcome [1]
388176
0
Change from Baseline in average duration of weekly RP attacks. This will be self recorded by the participant in the e-diary
Query!
Assessment method [1]
388176
0
Query!
Timepoint [1]
388176
0
The RP attacks will be assessed weekly.
Participants will be followed for 7 days following completion of the final Dosing period
Query!
Secondary outcome [2]
388177
0
Change from Baseline in average severity of weekly RP attacks. Severity is self marked by the participant as mild, moderate and severe using 11-point Likert scale.
Query!
Assessment method [2]
388177
0
Query!
Timepoint [2]
388177
0
The attacks are measured daily and recorded in the e-Diary and it is assessed by the researcher every day and analysed weekly.
Query!
Secondary outcome [3]
388178
0
Change from Baseline in average daily RCS.
The participant will be able to measure RCS score
Query!
Assessment method [3]
388178
0
Query!
Timepoint [3]
388178
0
This are self-recorded by the participants in the e-diary. This will be reviewed daily by the researchers, and analysed weekly for percentage change in the frequency of the attack.
Query!
Secondary outcome [4]
388179
0
Participants will be educated to use VAS. The outcome will be assessment of digital ulcer severity.
Query!
Assessment method [4]
388179
0
Query!
Timepoint [4]
388179
0
This are self-recorded by the participants in the e-diary. This will be reviewed daily by the researchers, and analysed for percentage change in the assessments (which will be conducted at Day 0 and Day 12)
Query!
Secondary outcome [5]
389292
0
Change from baseline in average pain score recorded during weekly RP attacks, as measured using a visual analogue scale (VAS)'
Query!
Assessment method [5]
389292
0
Query!
Timepoint [5]
389292
0
This are self-recorded by the participants in the e-diary. This will be reviewed daily from Day1 by the researchers, and analysed weekly for percentage change in the assessments up to 7 days from the last day of treatment
Query!
Secondary outcome [6]
389384
0
Change from baseline in net digital ulcer burden.
This are self-recorded by the participants in the e-diary. This will be reviewed daily from Day1 by the researchers, and analysed weekly for percentage change in the assessments up to 7 days from the last day of treatment
Query!
Assessment method [6]
389384
0
Query!
Timepoint [6]
389384
0
This are self-recorded by the participants in the e-diary. This will be reviewed daily from Day1 by the researchers, and analysed weekly for percentage change in the assessments up to 7 days from the last day of treatment
Query!
Secondary outcome [7]
389386
0
Change from baseline in participant quality of life measured using the Scleroderma Health Assessment Questionnaire (SHAQ)
Query!
Assessment method [7]
389386
0
Query!
Timepoint [7]
389386
0
This will occur at day 0 and day 12
Query!
Secondary outcome [8]
389387
0
The relevant metrics measured by an e-diary tool assess the severity of the attack -considering all symptoms of each attack (e.g. tingling, numbness, pain, colour changes)
Query!
Assessment method [8]
389387
0
Query!
Timepoint [8]
389387
0
This will be reviewed daily from Day1 by the researchers, and analysed weekly for percentage change in the assessments up to 7 days from the last day of treatment
Query!
Secondary outcome [9]
389388
0
Concomitant medication review will be assessed via consultation with the participant and review of medication charts and histories in the participants medial file,
Query!
Assessment method [9]
389388
0
Query!
Timepoint [9]
389388
0
This will be reviewed at an in-person clinic at Day 0, then self-recorded by the participants in the e-diary. daily from Day1-11 (reviewed electronically by the researchers), A final review will occur at an in-person clinic at day 12
Query!
Secondary outcome [10]
389389
0
One 4 mL blood sample will be obtained during each in-clinic visit within 2 to 6 hours of last dose of study drug in that Dosing Period as delineated in the Schedule of Assessment. The level of cilnidipine in blood will be measured following last dose of the Dosing Period
Query!
Assessment method [10]
389389
0
Query!
Timepoint [10]
389389
0
This is collected on Day 0 and 2-6 hours following final dose of each dosing period
Query!
Secondary outcome [11]
389393
0
Adverse events will be measured through out the study period from enrolment.
Vital signs are collected on Day 0 and During clinic visit after the last dose of the dosing period
Query!
Assessment method [11]
389393
0
Query!
Timepoint [11]
389393
0
daily for duration of study involvement (recorded in e-diary)
Query!
Secondary outcome [12]
393604
0
Raynaud's functional assessment will be conducted via digital examination by a physician delegated to the trial.
Query!
Assessment method [12]
393604
0
Query!
Timepoint [12]
393604
0
This will occur at day 0 and day 12
Query!
Secondary outcome [13]
393605
0
A pregnancy test for female participants of childbearing potential will be assessed using a urine sample
Query!
Assessment method [13]
393605
0
Query!
Timepoint [13]
393605
0
This will occur at day 0 and day 12
Query!
Secondary outcome [14]
393606
0
Thermography tests will be conducted on the most severely impacted digits (identified in screening) by a delegated trial nurses - and the results reviewed by the delegated trial physician
Query!
Assessment method [14]
393606
0
Query!
Timepoint [14]
393606
0
This will occur at Day 0 and day 12
Query!
Secondary outcome [15]
393608
0
Assessments for endothelial dysfunction will be performed using Endo-PAT with the results reviewed by a delegated physician
Query!
Assessment method [15]
393608
0
Query!
Timepoint [15]
393608
0
This will occur at Day 0 and day 12
Query!
Secondary outcome [16]
394163
0
Pharmacokinetic (PK) parameters will measure the level of cilnidipine in blood following last dose of each Dosing Period. All samples will be collected according to the PK sample manual, stored at -80 degree Celsius, shipped to and assessed by the central laboratory (Tetra Q, located in QLD).
Query!
Assessment method [16]
394163
0
Query!
Timepoint [16]
394163
0
PK samples will be collected at Day 0 and Day 12 of each Dosing period.
Query!
Eligibility
Key inclusion criteria
Participants at least 18 years of age diagnosed with severe secondary Raynaud’s disease (Raynaud’s Condition Score [RCS] greater than or equal to 40 and at least a 2-phase color change in fingers of pallor, cyanosis, and/or reactive hypermedia in response to cold exposure or emotion) mostly resulting from SSc and exhibiting regular and frequent RP attacks (averaging at least one attack per day) during the Screening period.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. A participant who meets any of the following exclusion criteria must be excluded from the study:
1. Primary Raynaud’s disease.
2. History of Raynaud’s attacks of sufficient severity as to require in-patient hospitalization (within the last 6 months).
3. The SBP of < 95 mm Hg during Randomization visit (Day 0).
4. Pulmonary hypertension requiring specific therapy for this condition.
5. Participants with an allergy to dihydropyridine CCBs that results in clinical findings such as profound hypotension, hives, rash, urticaria, wheezing and changes in breathing (Common treatment limiting adverse events [AEs] that occur with CCBs nifedipine and amlodipine such as edema, headache, heart rate changes, tachycardia, fatigue, constipation, flushing, drowsiness, dizziness should not limit enrollment into this study).
6. History of other chronic pain condition that could confound recording of pain scores during the study period.
7. Any prior or ongoing medical conditions, medical history, physical findings, or laboratory abnormality that in the opinion of the Investigator(s), would contraindicate administration of the study medication, or interfere with the study evaluations, or interfere with the participants ability to comply with the study protocol.
8. Cognitive or language difficulties that would impair completion of the study assessments.
9. Use of any investigational product (IP) or investigational medical device or participation in investigational drug studies within 30 days prior to enrollment in the study.
10. Those receiving nitrates, alpha blockers, PDE inhibitors (outside of stable administration for PAH), prostacyclins or endothelin antagonists.
11. History of orthostatic hypertension, dizziness or fainting spells, acute coronary or cerebrovascular event within 3 months of study enrollment.
12. History of major thoracic, abdominal, or vascular surgery within 6 months of study enrollment; History of sympathectomy.
13. Severe cardiomyopathy, severe valvular heart disease, chronic kidney disease (CKD) stage 3 or greater, evidence of malignancy, end stage lung disease.
14. Pregnant or lactating women.
15. Women of childbearing potential (WOCBP) unable to comply with contraceptive requirements during the study period.
16. Males with partners who are WOCBP and are unable to comply with the contraceptive requirements during the study.
17. History of drug or excess alcohol use that in the opinion of the Investigator(s) would affect the participant’s ability to reliably participate in the study. NHMRC guidelines for regular alcohol consumption in healthy adults are no more than 10 standard drinks per week and no more than four standard drinks on any one day.
18. Use of tobacco products of any type in the preceding one month and for the duration of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Participant will be randomized into different treatment by using a statistical software package through a computer
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Participant disposition will be analyzed using counts and percentages. The number and percentage of screened participants, enrolled participants, treated participants, participants discontinued from the study and study treatment, as well as the primary reason for discontinuation will be analyzed and listed.
Participant demography and baseline characteristics data will be summarized using descriptive statistics. The following demographic variables will be summarized by dose level: race, gender, age, height and weight, concomitant diseases (Hypertension, peripheral vascular disease, diabetes, CKD and stage, osteoporosis, history and type of heart arrhythmia).
In addition, the following baseline characteristics of Raynauds Disease will be summarized: age of onset, seasonality (months disease is worst), usual number of attacks/day, usual peak severity, baseline RCS assessment, how attacks are usually treated, how long attacks last in general, experience with other treatments both pharmacological and non-pharmacological.
Medical history terms will be coded using the MedDRA® Version 22.0 or higher. Medical history will be analyzed using descriptive statistics by MedDRA® SOC and PT.
Prior and concomitant medications will be coded using the most current version of the WHO drug dictionary available at the start of the study. Prior and concomitant medications will be listed by participant and summarized by treatment using anatomical therapeutic chemical (ATC) and preferred name.
Treatment compliance and exposure will be summarized and listed by treatment for all participants in the Safety population.
Analysis of Primary Endpoint - Percent change from baseline evaluation for frequency of weekly RP attacks will be the primary efficacy endpoint. Data collected in the last 7 days of each Dosing Period will be used for this analysis. Screening assessments will be used as baseline for the analysis of all periods. No multiple comparison adjustment will be used to control alpha for the multiple comparisons. Mixed effects model will be used for analysis of the primary endpoint according to the crossover design. Other efficacy endpoints of continuous variables will be analyzed using similar methodology. For nominal data, Chi-square tests will be applied. Generalized Estimating Equations method will be used, as appropriate, for adjusting for potential confounding factors. In addition, the final analysis will assess whether in this study of severe Raynaud’s disease participants, the minimally important difference, previously concluded of 14-15 points on the 100 point RCS scale (Khanna, 2010) has been achieved in the cilnidipine dose group. It also will record the percentage of participants achieving a PASS (34 point difference from baseline on a 0-100 VAS) (Khanna, 2010) in each treatment group.
The secondary endpoints of change from baseline evaluation will be compared among treatment groups using mixed effects model. Kaplan-Meier method will be used to evaluate time to event endpoints. To evaluate the impact of daily ambient temperature on symptomatic Raynaud’s attack, logistic regression will be used for temperature versus the occurrence of Raynaud’s attack (Yes/No). The effect of temperature on the severity score of Raynaud’s attacks and difference of using rescue medication between treatment groups will be evaluated by Chi-square test. The impact of therapy in sympathetic activity will be assessed by mixed model for repeated measures.
All safety assessments, including AEs, laboratory evaluations, vital signs, and other safety assessments will be analyzed using the Safety population.
Adverse events will be coded using the most current version of the MedDRA® Version 22.0 or higher. The analysis of AEs will be based on the concept of treatment emergent AEs. Treatment emergent AEs will be tabulated by treatment group and will include the number of participants for whom the event occurred, the severity, and relationship to study drug. Treatment emergent AEs (TEAEs) leading to discontinuation and SAEs with onset after the start of study drug will also be summarized.
All AEs and SAEs (including those with onset or worsening before the start of study drug) through the end of the study will be listed.
Baseline laboratory evaluations will be listed and summarized by treatment.
Vital signs (BP [systolic and diastolic], pulse rate, and oral temperature) will be listed and summarized by treatment and protocol specified collection time point. Observed and change from baseline will be summarized at each protocol specified collection time point.
Other Safety Assessments
The following assessments will be listed by participant:
• Pregnancy Test
• Raynaud’s function assessment by physician.
Pharmacokinetics
Plasma concentrations and actual blood sampling times will be listed by treatment and protocol specified time point and summarized using descriptive statistics — number of measurements, arithmetic mean, SD, and %CV, geometric mean, minimum, median, and maximum – at each scheduled time point. Individual and mean plasma concentration-time profiles will also be presented graphically for each treatment.
Pharmacokinetic parameters will be computed from the individual plasma concentrations using a non-compartmental approach.
Value for elimination rate constant (kel), elimination half-life (t½), Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf), apparent total clearance of the drug from plasma after oral administration (CL/F) or apparent volume of distribution during terminal phase after non-intravenous administration (Vz/F) will not be reported. Additional analyses will be performed as deemed necessary upon review of the data.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
28/05/2021
Query!
Actual
11/06/2021
Query!
Date of last participant enrolment
Anticipated
31/12/2022
Query!
Actual
Query!
Date of last data collection
Anticipated
31/01/2023
Query!
Actual
Query!
Sample size
Target
76
Query!
Accrual to date
23
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
18125
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [2]
18126
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
32119
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
32118
0
5042 - Bedford Park
Query!
Funding & Sponsors
Funding source category [1]
307051
0
Commercial sector/Industry
Query!
Name [1]
307051
0
AISA Pharma Australia Pty. Ltd.
Query!
Address [1]
307051
0
AISA Pharma Australia Pty Ltd
9 Adelaide Ave, East Lindfield 2070
Sydney, NSW, Australia
Query!
Country [1]
307051
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
AISA Pharma Australia Pty. Ltd.
Query!
Address
AISA Pharma Australia Pty Ltd
9 Adelaide Ave, East Lindfield 2070
Sydney, NSW, Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
307616
0
None
Query!
Name [1]
307616
0
Query!
Address [1]
307616
0
Query!
Country [1]
307616
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
307175
0
Southern Adelaide Clinical Human Research Ethics Committee
Query!
Ethics committee address [1]
307175
0
c/- Flinders Medical Centre 1 Flinders Drive BEDFORD PARK SA 5042
Query!
Ethics committee country [1]
307175
0
Australia
Query!
Date submitted for ethics approval [1]
307175
0
18/01/2021
Query!
Approval date [1]
307175
0
22/04/2021
Query!
Ethics approval number [1]
307175
0
2021/HRE00011
Query!
Summary
Brief summary
A randomized, placebo-controlled Phase 2a study to test the efficacy and safety of cilnidipine alone and in combination with tadalafil in participants at least 18 years of age diagnosed with severe secondary Raynaud’s disease (Raynaud’s Condition Score [RCS] greater than o r equal 40 and at least a 2-phase colour change in fingers of pallor, cyanosis, and/or reactive hypermedia in response to cold exposure or emotion) mostly resulting from SSc and exhibiting regular and frequent RP attacks (averaging at least one attack per day) during the Screening period. Double-blind, Placebo-controlled, Parallel-group, Dose Selection to assess the safety and efficacy of two doses of cilnidipine (10 mg and 20 mg), alone and in combination with tadalafil. Participants will be randomized to one of six prespecified treatment arms. During the study 36 participants will receive treatments in a blinded fashion. Placebo tablets (matching cilnidipine) and placebo capsules (matching tadalafil), for oral administration, will be provided to the site as well as the investigational treatments (cilnidipine and tadalafil). Medications will be dispensed during the preceding in-clinic study visit for self-administration by the participant. Each Dosing Period will last for 12 days (allowing for a variance window of -2 days [d10] or +2 days [d14] ) in which participants will take daily doses of assigned treatment in the morning. For each day of dosing, participants will take one capsule and one tablet to blind the active therapy being received. Dropouts will not be replaced. Primary Efficacy Endpoint: Percentage change from baseline in frequency of weekly RP attacks. Safety Endpoints: Incidence of adverse events (AEs) and serious adverse events (SAEs), including clinically significant vital signs from the time of randomization until 7 days following the last protocol dose.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
106298
0
Prof Michael Shanahan
Query!
Address
106298
0
Flinders University
Sturt Road
BEDFORD PARK SA 5042
Query!
Country
106298
0
Australia
Query!
Phone
106298
0
+61 8 8275 1819
Query!
Fax
106298
0
Query!
Email
106298
0
michael.shanahan@flinders.edu.au
Query!
Contact person for public queries
Name
106299
0
Erin Morton
Query!
Address
106299
0
Flinders University
Sturt Road
BEDFORD PARK SA 5042
Query!
Country
106299
0
Australia
Query!
Phone
106299
0
+61 468566663
Query!
Fax
106299
0
Query!
Email
106299
0
erin.morton@flinders.edu.au
Query!
Contact person for scientific queries
Name
106300
0
Meredith Todd
Query!
Address
106300
0
AISA Pharma Australia Pty Ltd
9 Adelaide Ave, East Lindfield 2070
Sydney, NSW, Australia
Mobile: 0432-663-121
Query!
Country
106300
0
Australia
Query!
Phone
106300
0
+61432 663 121
Query!
Fax
106300
0
Query!
Email
106300
0
mtodd@aisapharm.com
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF